
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington ?? Dermatologists have to remember not to do away with classical medicine and rely solely on molecular tests when making a diagnosis, according to a presenter at a meeting of the Society for Pediatric Dermatology here.